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The clinical presentation of noncystic ﬁbrosis bronchiectasis may be complicated by concomitant conditions, including gastro-
oesophageal reﬂux (GOR). Increased acidic GOR is principally caused by gastro-oesophageal junction incompetence and may
arise from lower oesophageal sphincter hypotension, including transient relaxations, hiatus hernia, and oesophageal dysmotility.
Speciﬁc pathophysiological features which are characteristic of respiratory diseases including coughing may further increase the
risk of GOR in bronchiectasis. Reﬂux may impact on lung disease severity by two mechanisms, reﬂex bronchoconstriction and
pulmonary microaspiration. Symptomatic and clinically silent reﬂux has been detected in bronchiectasis, with the prevalence of
26 to 75%. The cause and eﬀect relationship has not been established, but preliminary reports suggest that GOR may inﬂuence
the severity of bronchiectasis. Further studies examining the implications of GOR in this condition, including its eﬀect across the
disease spectrum using a combination of diagnostic tools, will clarify the clinical signiﬁcance of this comorbidity.
1.Introduction
Bronchiectasiswhichisunrelatedtocysticﬁbrosis(noncystic
ﬁbrosis bronchiectasis) is a chronic and progressive respira-
tory disease, associated with irreversible, abnormal dilation
ofthebronchiandbronchioles.Thereareamultitudeofaeti-
ologies, ranging from idiopathic to congenital conditions,
immunological disorders and postinfective causes [1]. The
spectrum of bronchiectasis is predominantly characterised
bychroniccough,sputumproduction,dyspnoea,andfatigue
[2, 3]. The clinical course is generally punctuated by infec-
tiousexacerbations[1]andtogether,thesefeaturesnegatively
impact on health-related quality of life in bronchiectasis
[4, 5].
Although the prevalence of bronchiectasis in patients
secondary to recurrent or severe infection has declined in
recent years [3, 6], it remains problematic and is associated
with signiﬁcant morbidity and mortality [6, 7]. A recent
study demonstrated persistent and progressive respiratory
symptoms and concurrent decline in lung function despite
ongoing medical intervention over an eight-year period
[7]. The goals of management are multifaceted, aiming to
minimise the frequency and severity of exacerbations, rate
of pulmonary decline, and to maximise secretion clearance.
This is achieved through antibiotic therapy, inhalation
therapy, and physiotherapy [1, 8].
The clinical presentation of bronchiectasis may be com-
plicated by the coexistence of other medical conditions or
comorbidities, including gastro-oesophageal reﬂux (GOR)
[9]. GOR refers to the regurgitation of gastric contents
into the oesophagus, with 24hr oesophageal pH monitoring
providing a comprehensive quantiﬁcation of GOR in the
distal and proximal oesophagus [10]. A comorbidity such as
GOR may reduce health-related quality of life and accelerate
the rate of pulmonary decline and progression of bronchiec-
tasis [1]. Understanding the extent of GOR and the clinical2 Pulmonary Medicine
relevance of a concomitant diagnosis in bronchiectasis is
important in the overall management of this condition.
2.Pathological Reﬂux
In deﬁning GOR, it is important to acknowledge that the
process of occasional reﬂux of gastric contents into the
oesophagus is a normal physiological event [11]. Generally,
such episodes occur ﬁve times during the postprandial hour,
with their frequency declining rapidly to a baseline of zero
approximately one to two hours after post prandial [11].
Most episodes are restricted to the distal oesophagus, are of
brief duration, cleared rapidly, and generally well tolerated
[12].Incontrast,pathologicalGORhasbeendescribedasthe
increased frequency or duration of exposure of the oesopha-
gus to regurgitated gastric contents [13]. The frequency and
durationofepisodes,aswellasthevolume,composition,and
destination of the gastro-oesophageal reﬂuxate are all factors
determining its signiﬁcance.
Dysfunction of the oesophago-gastric junction is a
prerequisiteforthedevelopmentofGOR.Thecompetenceof
this barrier is the product of its anatomical and physiological
features [14]. This antireﬂux barrier is dynamic and is
required to provide protection from reﬂux during diﬀerent
physiological circumstances [12]. When the aggressive forces
(acidreﬂux)outweighthedefensiveforces(antireﬂux barrier
and oesophageal clearance), the end result is GOR. The
intermittentnatureofGORinsomeindividualssuggeststhat
these forces are delicately balanced.
The aetiology of GOR is multifactorial and includes
gastro-oesophageal junction incompetence, characterised by
transient lower oesophageal sphincter (LOS) relaxation,
hypotensive LOS, and hiatus hernia [15–17]. There are
factors speciﬁc to pulmonary diseases which may also con-
tribute to the development or occurrence of GOR, including
physiological changes in respiratory mechanics. During
inspiration, a raised intraabdominal pressure increases the
risk of GOR [16]. Both airﬂow obstruction and hyper-
inﬂation are believed to interfere with the diaphragmatic
crural support augmenting LOS pressure [18], although the
possible contribution of respiratory mechanics to GOR in
chronic lung disease remains unclear [16, 17, 19].
Chronic reduction in LOS tone can also be associated
with GOR by the mechanism of stress reﬂux, where a
hypotensive LOS is overcome by an abrupt increase in
intraabdominal pressure, such as during coughing [15, 16].
The temporal association between coughing and episodes of
reﬂux has been demonstrated in patients with chronic cough
and asthma [20, 21], which suggests that a self-perpetuating
positive feedback cycle of cough stimulating reﬂux may
occur in patients with preexisting pulmonary disease [21].
Other potential factors which may inﬂuence GOR include
oesophageal acid clearance. Oesophageal acid clearance is
dependent on eﬀective oesophageal emptying. Prolongation
of acid clearance secondary to oesophageal dysmotility,
with low amplitude oesophageal contractions and abnormal
peristalsis, has been documented in patients with asthma
and chronic bronchitis [22, 23].
There are two principle mechanisms by which GOR may
impact on respiratory disease severity. The ﬁrst is vagally
mediated reﬂex bronchoconstriction [24]. Oesophageal acid
in the distal oesophagus stimulates airway irritation and
an inﬂammatory response, with the release of potent
mediators of bronchoconstriction [25], which are associated
with coughing and reﬂux-induced bronchoconstriction in
patients with asthma [21]. The second mechanism is pul-
monary microaspiration. During microaspiration, reﬂuxed
gastric material reaches the proximal oesophagus and moves
into the hypopharynx with the potential to enter the larynx
or the trachea [24].
In addition to these pathophysiological mechanisms,
aspects of physiotherapy management of bronchiectasis may
inﬂuence the frequency of GOR. Previous studies have
demonstrated that airway clearance techniques to facilitate
sputum expectoration involving gravity-assisted drainage
with a head down tilt provoke GOR in patients with cystic
ﬁbrosis [26]. This is a type of therapy regularly prescribed
by physiotherapists for individuals with bronchiectasis [27],
althoughtheimpactofthisairwayclearancetechniqueonthe
frequency of reﬂux episodes in this population has not been
studied.
The interaction between chronic respiratory diseases and
GOR is not yet fully deﬁned, nor has cause and eﬀect been
clearly established. Similarly, the precise nature of the rela-
tionship between GOR and bronchiectasis remains elusive.
Some individuals may have two independent conditions
which merely coexist; in others, a concomitant diagnosis of
GOR may have signiﬁcant clinical implications. In view of
this,thediagnosticapproachtoGORinpatientswithchronic
respiratory conditions, including bronchiectasis may require
careful consideration, with an accurate diagnosis remaining
a clinical challenge.
3.DiagnosticTools
Comprehensive symptom evaluation is important with
weekly experience of heartburn and/or acid regurgitation
considered a strong diagnostic indicator of GOR [28]. How-
ever, symptom questionnaires focus on the presence of gas-
trointestinal symptoms alone, which limits their application
to patients with occult or clinically silent GOR. Even with the
recognitionthatrespiratorymanifestations,includingcough,
wheezing, and dyspnoea may be an atypical presentation
of GOR beyond the oesophagus [29, 30], these symptoms
are common amongst patients with bronchiectasis, and their
ability to distinguish a diagnosis of GOR has not been fully
determined.
Ambulatory intraoesophageal pH monitoring is per-
formed with a pH probe passed nasally and positioned 5cm
above the LOS and this detects reﬂux episodes by a drop in
pHtolessthan4[31].Themajorityoftheliteratureindicates
that ambulatory 24hr oesophageal pH monitoring yields the
highest sensitivity and speciﬁcity of all diagnostic tests of
GOR with up to 98% and 96%, respectively, [32]. Dual-
channel oesophageal pH monitoring allows the recording
of proximal oesophageal reﬂux [33] .T h ei m p o r t a n c eo fPulmonary Medicine 3
nonacid, liquid, and a mixture of gas and liquid reﬂux
has been highlighted with the application of multichannel
intraluminal impedance monitoring, which allows recording
of GOR at all pH levels and measurement of the air-liquid
compositionofthereﬂuxate[34].Thisisemergingasauseful
tool for diagnosing nonacid and weakly acidic reﬂuxate
[35,36]andhasbeenappliedinotherrespiratoryconditions,
including cystic ﬁbrosis [37, 38]. It is yet to be used in the
bronchiectasis population.
Detection of pulmonary microaspiration is even more
diﬃcult. Nuclear scintography is used as a semiquantitative
test for detection of microaspiration secondary to GOR, but
the small volume required to induce bronchospasm may
escape detection or may occur intermittently [39]. Recent
studies have explored noninvasive methods of measuring
microaspiration. The detection of pepsin as a surrogate
marker of GOR has been examined using pepsin assays
in sputum and saliva samples, yielding a sensitivity and
speciﬁcity of 75% and 91%, respectively, compared to
proximal pH monitoring [40]. More recent studies have
tested bronchoalveolar lavage ﬂuid for pepsin and bile
salts, providing evidence of aspiration of gastric contents
into the lower respiratory tract in patients with cystic
ﬁbrosis and lung transplant recipients [37, 38, 41, 42].
Another method is exhaled breath condensate. Exhaled
breath condensate provides a noninvasive quantiﬁcation of
endogenous airway pH, with low pH levels in exhaled breath
condensate demonstrated in patients with stable respiratory
disease, including asthma, cystic ﬁbrosis, chronic obstructive
pulmonary disease, and bronchiectasis [43, 44]. While the
clinical utility of exhaled breath condensate in the diagnosis
ofpulmonary microaspirationhasnot beenfullydetermined
in lung disease, it is a promising noninvasive option.
4.GORinBronchiectasis
Amongst the disparate aetiologies of bronchiectasis, it has
been hypothesised that GOR is a potential cause of this
condition, with aspiration into the tracheobronchial tree
hypothesised to present as insidious-onset bronchiectasis,
via gastric acid-induced erosion triggering chronic airway
inﬂammation [3, 45]. Helicobacter pylori (HP) has been
identiﬁed as the microorganism which causes gastritis [46],
and a high seroprevalence (76%) of HP in patients with
bronchiectasis has been detected [47]. It has been proposed
that inhalation or aspiration of HP exotoxins may contribute
to chronic airway inﬂammation in patients with idiopathic
bronchiectasis [47]. However, in the same cohort of patients,
symptoms of heartburn and acid regurgitation were not
linked with high levels of serum HP, and concurrent
oesophageal pH monitoring was not included to conﬁrm a
diagnosis of GOR [9]. A later study failed to demonstrate HP
in bronchial specimens in patients with bronchiectasis aris-
ing from a variety of aetiologies [48]. With these disparate
results, the possible pathogenic role of HP in bronchiectasis
requires further study.
Several studies have explored the causal relationship
between GOR and bronchiectasis in the paediatric pop-
ulation with conﬁrmed bronchiectasis. Using a mix of
diagnostic tools, including distal channel oesophageal pH
monitoring, barium oesophagogram and radiological ﬁnd-
ings, these reviews suggested that GOR is the causative factor
in 3% to 32% of paediatric patients with bronchiectasis
[49, 50].
GOR is also a suggested cause of idiopathic bronchiecta-
sis in the adult population, with the presence of upper gas-
trointestinal symptoms, including epigastric pain, abdomi-
nal distention, vomiting, heartburn, and acid regurgitation
identiﬁed in 32% out of a cohort of 100 patients, 82% of
whom had idiopathic bronchiectasis [9, 47]. In an equally
large study of 100 adults with bronchiectasis, GOR was
identiﬁed as a causative factor in 3% of patients, based on
gastrointestinal symptoms and symptomatic improvement
following commencement of antireﬂux medication [51].
Shoemark and colleagues [52] found aspiration to be a cause
of bronchiectasis in 1% of patients. While these reports
suggest a degree of causality, the lack of objective diagnostic
conﬁrmation of GOR implies that further clariﬁcation is
necessary in patients with idiopathic bronchiectasis using an
objective measurement of GOR.
Asymptomatic (clinically silent) nocturnal GOR was
diagnosed in a group of 25 patients with a range of
respiratory conditions, including bronchiectasis, using a
barium oesophagogram, with only 40% of patients reporting
heartburn and 16% reporting dysphagia [45]. This study was
one of the ﬁrst to highlight the signiﬁcance of objective tools
to conﬁrm a diagnosis of GOR. Since this early report, a
further ﬁve studies have evaluated the prevalence of GOR
and its clinical signiﬁcance in patients with bronchiectasis,
using a combination of symptomatic and objective tools.
Symptomatic evaluation found that 32% of 100 patients
with bronchiectasis experienced epigastric pain, abdominal
distension, vomiting, heartburn, or acid regurgitation [9].
The signiﬁcance of these symptoms is highlighted by the
reduced lung function associated with acid regurgitation and
thelinkbetweenepigastricpainandahighernumberoflobes
aﬀected by bronchiectasis [9]. While this provided a glimpse
into the potential impact of GOR on respiratory function in
bronchiectasis, these ﬁndings remain limited to those with
typical GOR symptoms.
Four studies have examined GOR in bronchiectasis using
24hr oesophageal pH monitoring. A pilot study of 19
patients with bronchiectasis utilized simultaneous tracheal
and oesophageal pH monitoring [53]. A total of eight
patients demonstrated reﬂux based on the DeMeester score
[53]. Of those with GOR, 88% experienced symptoms of
heartburn, nocturnal cough, or disturbed sleep compared to
those without reﬂux. While the results are suggestive that a
proportion of patients with bronchiectasis have distal reﬂux
with associated nocturnal symptoms, no microaspiration of
gastric contents was demonstrated with tracheal monitoring
[53].
In four patients with end-stage bronchiectasis, who
completed dual-channel oesophageal pH monitoring, the
prevalenceofdistalreﬂuxof75%andproximalreﬂuxof50%4 Pulmonary Medicine
suggests that patients with more severe bronchiectasis may
be more likely to have GOR [54]. However, the relationship
of reﬂux to clinical presentation or its association with lung
disease severity was not evaluated [54]. Similar results were
found in a study of seven patients with advanced bronchiec-
tasis awaiting lung transplantation, with 33% experiencing
an increased number of distal reﬂux episodes, speciﬁcally in
the supine position [55]. In addition, manometry studies
showed LOS hypotonia in 57% of those patients with
upper oesophageal sphincter hypotonia in 14% of patients.
This suggests that the gastrointestinal contributions to
GOR which have been identiﬁed in patients with chronic
obstructivepulmonarydisease,cysticﬁbrosis,andinterstitial
lung disease [54, 55] may also be apparent in bronchiectasis.
In the largest prospective study to date of a group of
58 patients with nontuberculous mycobacterium lung dis-
ease with associated bronchiectasis, GOR was diagnosed in
26%, with clinically silent reﬂux in 73% [56]. Neither
the presence of typical symptoms of heartburn nor acid
regurgitation were predictive of GOR. However, those with
GOR demonstrated more extensive bronchiectasis on high
resolution computed tomography and bronchiolitis, with
more lobes aﬀected compared to those without GOR [56],
which illustrates the potential clinical implications of GOR.
These studies suggest that GOR is a comorbidity in
selectedpatientswithbronchiectasis,andthereportedpreva-
lence is currently higher compared to the general population
(range of 10 to 20%) [57]. While the understanding of GOR
and its relationship to bronchiectasis have been signiﬁcantly
enhanced by studies using oesophageal pH monitoring, it is
evident that the clinical presentation may not include typical
symptoms of GOR, emphasising the ongoing value of objec-
tive evaluation. GOR is associated with a decreased health-
related quality of life in individuals without lung disease who
havesymptomsofheartburnandacidregurgitation[58],but
the degree of compromise to health-related quality of life in
patients with bronchiectasis has not been examined. These
clinical consequences are worthy of future study.
5. Current Therapy and Management
Current therapy for GOR focuses on modifying risk factors,
inhibiting the production of gastric acid and enhancing
oesophageal and gastric motility. Recommended lifestyle
changes to reduce the incidence of reﬂux include avoidance
of potential dietary triggers and meals approximately two
hours before recumbence with elevation of the head of the
bed for those with nocturnal GOR [59]. Medical approaches
include the use of Antacids, Histamine antagonists, and
Proton pump inhibitors. The beneﬁcial eﬀect of Antacids
is related to the neutralization of acid, which provides
temporary symptomatic relief [60]. Proton pump inhibitors
andHistamineantagonistsinhibitgastricacidsecretion,with
Proton pump inhibitors being the more eﬀective agent [60].
In the absence of amelioration in symptoms or persistence
of the underlying mechanism causing GOR, surgery is an
additional option. The direct eﬀects of these approaches in
patients with bronchiectasis are unknown. With respect to
the surgical management, fundoplication in two patients
with advanced bronchiectasis was associated with improve-
ment in lung function and reduction in oxygen requirements
[61, 62]. Further exploration of the management of GOR in
bronchiectasis is required.
6. Conclusions
Although the prevalence of bronchiectasis has declined in
recent years, a low index of clinical suspicion persists with
this disease [63]. Regardless of the source of bronchiectasis,
the possible contribution of GOR to rate of decline in
lung function requires further evaluation. In addition,
the symptoms of GOR in patients with bronchiectasis in
diﬀering clinical states are unclear. With acute exacerbations
accompanying the clinical course of this condition, it would
beworthytonotethepatternandfrequencyofGORepisodes
inpatientswhoareacutelyunwell.Thiscouldprovideinsight
into the possible contribution of this comorbidity to the
progression and prognosis of bronchiectasis. The pathogen-
esis and features of GOR in patients with bronchiectasis are
complex and the application of a range of reliable diagnostic
tests to identify the extent of the comorbidity and its
speciﬁc features, including acidic, weakly acidic, non-acid or
duodenogastric reﬂux, and pulmonary microaspiration are
important. Further work is required to identify any speciﬁc
gastro-oesophageal features or respiratory mechanics which
mayheightentheriskofGORinpatientswithbronchiectasis.
Finally, the optimal treatment approaches for managing
GOR in this population are yet to be established.
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